13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-000700-29-BE (EUCTR) | 12/03/2018 | 08/01/2018 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS SA | NULL | Not Recruiting | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Germany;Netherlands;Sweden | ||
| 2 | EUCTR2016-000700-29-HU (EUCTR) | 27/02/2018 | 28/12/2017 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS SA | NULL | Not Recruiting | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;Italy;United Kingdom;Hungary;Czech Republic;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden | ||
| 3 | EUCTR2016-000700-29-PL (EUCTR) | 15/02/2018 | 15/01/2018 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS SA | NULL | Not Recruiting | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Netherlands;Germany;Sweden | ||
| 4 | EUCTR2016-000700-29-SE (EUCTR) | 07/08/2017 | 14/11/2016 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized-double blind placebo-controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS SA | NULL | Not Recruiting | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;Italy;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden | ||
| 5 | EUCTR2016-000700-29-DE (EUCTR) | 08/03/2017 | 16/11/2016 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS SA | NULL | Not Recruiting | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;Italy;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden | ||
| 6 | EUCTR2016-000700-29-ES (EUCTR) | 10/02/2017 | 09/12/2016 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study. - SPI2 | Multiple sclerosis MedDRA version: 19.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS SA | NULL | Not Recruiting | Female: yes Male: yes | 375 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Germany;United Kingdom;Italy;Sweden | ||
| 7 | EUCTR2016-000700-29-CZ (EUCTR) | 01/02/2017 | 10/11/2016 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study. - SPI2 | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: MD1003 INN or Proposed INN: D-BIOTIN | MEDDAY PHARMACEUTICALS SA | NULL | Not Recruiting | Female: yes Male: yes | 754 | Phase 3 | United States;Spain;Turkey;Italy;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden | ||
| 8 | EUCTR2016-000700-29-IT (EUCTR) | 30/01/2017 | 05/11/2020 | Effect of MD1003 in progressive multiple sclerosis with walking impairment | Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study - SPI2 | Multiple sclerosis MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: D-Biotin Product Code: [MD1003] INN or Proposed INN: D-BIOTINA Other descriptive name: - | MEDDAY PHARMACEUTICALS | NULL | Not Recruiting | Female: yes Male: yes | 754 | Phase 3 | United States;Czechia;Spain;Turkey;Italy;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden |